FDA, Tirzepatide

The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
FDA says tirzepatide shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
This Popular Weight Loss Drug Can Now Be Used To Treat Sleep Apnea
Zepbound is the first medication approved to treat people with obstructive sleep apnea, said Sailly Seymor, director of FDA's division of pulmonology, allergy, and critical care.
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
FDA says shortage of GLP-1 drug tirzepatide is over
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
McKnight's Long-Term Care News33m
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
STAT5d
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
MedPage Today6d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Everyday Health2d
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
JD Supra2d
FDA Releases Declaratory Order Regarding Tirzepatide Shortage
The FDA released a Declaratory Order on December 19th re-evaluating and essentially re-instituting its previous position on the tirzepatide ...
STAT5d
Is a contrarian leader good for the FDA?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.